Disease · MONDO_0010434

synovial sarcoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. synovial sarcoma. Diseases, record MONDO_0010434. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0010434

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: synovial sarcoma; Open Targets
Open Targets ID: MONDO_0010434; Open Targets
Other names: Synovialosarcoma, sarcoma, synovial, malignant, synovial sarcoma (disease); Open Targets
Disease Ontology: DOID:5485; Disease Ontology
MeSH: D013584; MeSH
NCI Thesaurus: C3400; NCI Thesaurus
Orphanet: ORPHA:3273; Orphanet
Highest stage of its drugs: Approval, for 1 of its 48 drugs, from FDA; Open Targets

Drugs48

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
AFAMITRESGENE AUTOLEUCEL	CHEMBL4802254	Gene	Approval	FDA	1	0	0	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
FLUDARABINE	CHEMBL1568	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
IFOSFAMIDE	CHEMBL1024	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
DOCETAXEL	CHEMBL3545252	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
DOXORUBICIN HYDROCHLORIDE	CHEMBL359744	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ETOPOSIDE	CHEMBL44657	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
TRABECTEDIN	CHEMBL450449	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
CATEQUENTINIB	CHEMBL4303201	Small molecule	Phase 3	ClinicalTrials.gov and TTD	2	1	1	Drugs and targets

1 to 10 of 48

See all 48 drugs

Targets86

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	4	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3791	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	3	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2324	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	3	Stem cell growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	3	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/5159	Drugs and targets
TOP2A	DNA topoisomerase 2-alpha	3	DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor	Phase 3	https://conductscience.org/library/genes/7153	Drugs and targets
TUBA1A	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets

1 to 10 of 86

See all 86 targets

Trials47

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00642941	A Study of R1507 in Participants With Recurrent or Refractory Sarcoma	Phase 2	317	2021-02-03	Sarcoma	TEPROTUMUMAB	Its record names the disease	ClinicalTrials.gov
NCT00668148	A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma	Phase 2	113	2018-07-17	Ewing's Sarcoma /Peripheral Neuroectodermal Tumor (PNET), Rhabdomyosarcoma, Leiomyosarcoma, Adipocytic Sarcoma, Synovial Sarcoma	CIXUTUMUMAB	Its record names the disease	ClinicalTrials.gov
NCT02601937	EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma	Phase 1	109	2024-10-03	Rhabdoid Tumors, INI1-negative Tumors, Synovial Sarcoma, Malignant Rhabdoid Tumor of Ovary	TAZEMETOSTAT	Its record names the disease	ClinicalTrials.gov
NCT02609984	Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)	Phase 2	89	2020-05-14	Sarcoma, Myxoid/Round Cell Liposarcoma, Synovial Sarcoma, Metastatic Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Locally Advanced Sarcoma, Liposarcoma	ATEZOLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02452554	Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma	Phase 2	62	2019-08-29	Pleuropulmonary Blastoma, Recurrent Malignant Peripheral Nerve Sheath Tumor, Recurrent Neuroblastoma, Recurrent Rhabdomyosarcoma, Recurrent Synovial Sarcoma, Wilms Tumor	LORVOTUZUMAB MERTANSINE	Its record names the disease	ClinicalTrials.gov
NCT02815995	Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes	Phase 2	57	2025-06-12	Advanced and/or Metastatic Sarcoma	DURVALUMAB, TREMELIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT01343043	A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma	Phase 1	50	2020-07-09	Neoplasms	CYCLOPHOSPHAMIDE, FLUDARABINE	Its record names the disease	ClinicalTrials.gov
NCT03063632	Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma	Phase 2	28	2022-08-30	Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Synovial Sarcoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Refractory Mycosis Fungoides and Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7, Unresectable Synovial Sarcoma	INTERFERON GAMMA-1B, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT04145700	CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma	Phase 1/2	23	2023-09-13	Synovial Sarcoma	DOCETAXEL, GEMCITABINE, RAMUCIRUMAB	Its record names the disease	ClinicalTrials.gov
NCT04939701	Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants	Phase 1/2	16	2024-08-06	Ovarian Cancer, NSCLC, ESCC, Solid Tumors	PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 47

See all 47 trials

Comparisons in its trials17

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
CMB305 (Sequentially Administered LV305 and G305)+Atezolizumab vs Atezolizumab: deaths from any cause	31 of 45	27 of 44	89	NCT02609984	Trial comparisons
CMB305 (Sequentially Administered LV305 and G305)+Atezolizumab vs Atezolizumab: Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)	6 of 45	6 of 43	88	NCT02609984	Trial comparisons
CMB305 (Sequentially Administered LV305 and G305)+Atezolizumab vs Atezolizumab: Number of Participants Who Experienced At Least One Adverse Event (AE)	44 of 45	43 of 43	88	NCT02609984	Trial comparisons
CMB305 (Sequentially Administered LV305 and G305)+Atezolizumab vs Atezolizumab: serious adverse events	17 of 45	9 of 43	88	NCT02609984	Trial comparisons
CMB305 (Sequentially Administered LV305 and G305)+Atezolizumab vs Atezolizumab: Number of Participants Positive for Anti-New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1) Antibody at Baseline	14 of 35	6 of 29	64	NCT02609984	Trial comparisons
CMB305 (Sequentially Administered LV305 and G305)+Atezolizumab vs Atezolizumab: Number of Participants Positive for Anti-New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1) Antibody After Induction With Treatment	16 of 32	0 of 27	59	NCT02609984	Trial comparisons
CMB305 (Sequentially Administered LV305 and G305)+Atezolizumab vs Atezolizumab: Number of Participants Positive for Anti-New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1) T Cells at Baseline	17 of 27	12 of 24	51	NCT02609984	Trial comparisons
CMB305 (Sequentially Administered LV305 and G305)+Atezolizumab vs Atezolizumab: Number of Participants Positive for Anti-New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1) T Cells After Induction With Treatment	14 of 26	3 of 20	46	NCT02609984	Trial comparisons
Group I (Pembrolizumab, Interferon Gamma-1b) vs Group II (Pembrolizumab, Interferon Gamma-1b): Overall Response Rate (ORR)	6 of 16	0 of 12	28	NCT03063632	Trial comparisons
Group I (Pembrolizumab, Interferon Gamma-1b) vs Group II (Pembrolizumab, Interferon Gamma-1b): Incidence of Adverse Events	15 of 16	12 of 12	28	NCT03063632	Trial comparisons

1 to 10 of 17

See all 17 comparisons in its trials

Papers from its trials27

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
23554566	RESULT	1	PubMed
19451433	RESULT	1	PubMed
18448563	RESULT	1	PubMed
18286501	RESULT	1	PubMed
40934647	DERIVED	1	PubMed
39687431	DERIVED	1	PubMed
38232337	DERIVED	1	PubMed
36075914	DERIVED	1	PubMed
35934010	DERIVED	1	PubMed
34482181	DERIVED	1	PubMed

1 to 10 of 27

See all 27 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0010434

GET https://conductscience.org/api/diseases/v1/MONDO_0010434/drugs?page=2

API reference For AI assistants